NASDAQ:PODDInsulet Stock Price, Forecast & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD shares have increased by 18.2% and is now trading at $203.36.
View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) announced its earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.01. The medical instruments supplier earned $198 million during the quarter, compared to analyst estimates of $189.61 million. Insulet had a return on equity of 7.66% and a net margin of 0.66%. The firm's quarterly revenue was up 23.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.07 earnings per share.
View Insulet's earnings history.

Insulet issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $210.792-217.877 million, compared to the consensus revenue estimate of $201.99 million.

20 analysts have issued 12 month price objectives for Insulet's shares. Their forecasts range from $140.00 to $250.00. On average, they anticipate Insulet's share price to reach $198.26 in the next year. This suggests that the stock has a possible downside of 2.5%.
View analysts' price targets for Insulet.

Headlines about PODD stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insulet earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Steris (STE) and ABIOMED (ABMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (1.29%), Sumitomo Mitsui Trust Holdings Inc. (0.49%), Columbus Circle Investors (0.37%), Beacon Investment Advisory Services Inc. (0.37%), First Trust Advisors LP (0.29%) and Scout Investments Inc. (0.18%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Chartwell Investment Partners LLC, First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc., Scout Investments Inc., SG Americas Securities LLC, Mackay Shields LLC, Beacon Investment Advisory Services Inc., and MAI Capital Management. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including SeaTown Holdings Pte. Ltd., Jag Capital Management LLC, Frontier Capital Management Co. LLC, Columbus Circle Investors, State of Alaska Department of Revenue, Assenagon Asset Management S.A., UBS Group AG, and National Asset Management Inc..
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $203.36.

Insulet has a market capitalization of $12.83 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]